These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32342504)

  • 1. Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination.
    McClymont E; Lee M; Raboud J; Coutlée F; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Klein MB; Harris M; Cohen J; Yudin MH; Wobeser W; Money D
    Int J Gynaecol Obstet; 2020 Jul; 150(1):108-115. PubMed ID: 32342504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV types, cervical high-grade lesions and risk factors for oncogenic human papillomavirus infection among 3416 Tanzanian women.
    Mchome BL; Kjaer SK; Manongi R; Swai P; Waldstroem M; Iftner T; Wu C; Mwaiselage J; Rasch V
    Sex Transm Infect; 2021 Feb; 97(1):56-62. PubMed ID: 32269071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV.
    McClymont E; Coutlée F; Lee M; Albert A; Raboud J; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Klein MB; Yudin MH; Harris M; Wobeser W; Bitnun A; Samson L; Money D;
    J Acquir Immune Defic Syndr; 2020 Mar; 83(3):230-234. PubMed ID: 31917750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of HPV infection over time in European women who are HIV-1 positive.
    Heard I; Cubie HA; Mesher D; Sasieni P;
    BJOG; 2013 Jan; 120(1):41-9. PubMed ID: 23121095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study.
    Na YJ; Jeong O; Seong J; Lee J; Lee SY; Hur S; Ryou S
    J Gynecol Oncol; 2024 Sep; 35(5):e56. PubMed ID: 38330379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.
    Kang YJ; Lewis H; Smith MA; Simonella L; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2015 Aug; 15():365. PubMed ID: 26297490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark - the SHADE.
    Thorsteinsson K; Ladelund S; Storgaard M; Katzenstein TL; Johansen IS; Pedersen G; Rönsholt FF; Nielsen LN; Nilas L; Franzmann M; Obel N; Lebech AM; Bonde J
    BMC Infect Dis; 2019 Aug; 19(1):740. PubMed ID: 31438877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
    J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination.
    Jalilvand S; Shoja Z; Nourijelyani K; Tohidi HR; Hamkar R
    J Med Virol; 2015 Feb; 87(2):287-95. PubMed ID: 25156655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 16. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
    BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
    Castle PE; Solomon D; Schiffman M; Wheeler CM
    J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.